Switch theme
Sign up to access all valuation multiples
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
2005
136
LTM Revenue $86.4M
LTM EBITDA -$109M
$329M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AnaptysBio has a last 12-month revenue (LTM) of $86.4M and a last 12-month EBITDA of -$109M.
In the most recent fiscal year, AnaptysBio achieved revenue of $91.3M and an EBITDA of -$92.7M.
AnaptysBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AnaptysBio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $86.4M | XXX | $91.3M | XXX | XXX | XXX |
| Gross Profit | $86.4M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$109M | XXX | -$92.7M | XXX | XXX | XXX |
| EBITDA Margin | -126% | XXX | -102% | XXX | XXX | XXX |
| EBIT | -$127M | XXX | -$115M | XXX | XXX | XXX |
| EBIT Margin | -147% | XXX | -126% | XXX | XXX | XXX |
| Net Profit | -$155M | XXX | -$145M | XXX | XXX | XXX |
| Net Margin | -179% | XXX | -159% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AnaptysBio's stock price is $22.
AnaptysBio has current market cap of $653M, and EV of $329M.
See AnaptysBio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $329M | $653M | XXX | XXX | XXX | XXX | $-5.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AnaptysBio has market cap of $653M and EV of $329M.
AnaptysBio's trades at 3.6x EV/Revenue multiple, and -3.5x EV/EBITDA.
Equity research analysts estimate AnaptysBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AnaptysBio has a P/E ratio of -4.2x.
See valuation multiples for AnaptysBio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $653M | XXX | $653M | XXX | XXX | XXX |
| EV (current) | $329M | XXX | $329M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | -3.0x | XXX | -3.5x | XXX | XXX | XXX |
| EV/EBIT | -2.6x | XXX | -2.9x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.2x | XXX | -4.5x | XXX | XXX | XXX |
| EV/FCF | 16.7x | XXX | -2.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnaptysBio's last 12 month revenue growth is -3%
AnaptysBio's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.5M for the same period.
AnaptysBio's rule of 40 is -837% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AnaptysBio's rule of X is -133% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AnaptysBio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -3% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | -126% | XXX | -102% | XXX | XXX | XXX |
| EBITDA Growth | -6% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -837% | XXX | -104% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -133% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 179% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 226% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AnaptysBio acquired XXX companies to date.
Last acquisition by AnaptysBio was XXXXXXXX, XXXXX XXXXX XXXXXX . AnaptysBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AnaptysBio founded? | AnaptysBio was founded in 2005. |
| Where is AnaptysBio headquartered? | AnaptysBio is headquartered in United States of America. |
| How many employees does AnaptysBio have? | As of today, AnaptysBio has 136 employees. |
| Who is the CEO of AnaptysBio? | AnaptysBio's CEO is Mr. Daniel R. Faga. |
| Is AnaptysBio publicy listed? | Yes, AnaptysBio is a public company listed on NAS. |
| What is the stock symbol of AnaptysBio? | AnaptysBio trades under ANAB ticker. |
| When did AnaptysBio go public? | AnaptysBio went public in 2017. |
| Who are competitors of AnaptysBio? | Similar companies to AnaptysBio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of AnaptysBio? | AnaptysBio's current market cap is $653M |
| What is the current revenue of AnaptysBio? | AnaptysBio's last 12 months revenue is $86.4M. |
| What is the current revenue growth of AnaptysBio? | AnaptysBio revenue growth (NTM/LTM) is -3%. |
| What is the current EV/Revenue multiple of AnaptysBio? | Current revenue multiple of AnaptysBio is 3.8x. |
| Is AnaptysBio profitable? | Yes, AnaptysBio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AnaptysBio? | AnaptysBio's last 12 months EBITDA is -$109M. |
| What is AnaptysBio's EBITDA margin? | AnaptysBio's last 12 months EBITDA margin is -126%. |
| What is the current EV/EBITDA multiple of AnaptysBio? | Current EBITDA multiple of AnaptysBio is -3.0x. |
| What is the current FCF of AnaptysBio? | AnaptysBio's last 12 months FCF is $19.7M. |
| What is AnaptysBio's FCF margin? | AnaptysBio's last 12 months FCF margin is 23%. |
| What is the current EV/FCF multiple of AnaptysBio? | Current FCF multiple of AnaptysBio is 16.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
